ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Diabetes"

  • Abstract Number: 397 • 2016 ACR/ARHP Annual Meeting

    Comorbidities Associated with Pediatric Psoriatic Arthritis

    Cynthia Manos1, Rui Xiao2, Alexis Ogdie3, Timothy Brandon4 and Pamela F. Weiss5,6, 1Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, 5Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 6Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: In adults, psoriatic arthritis (PsA) is associated with an increased prevalence of obesity, hypertension, and diabetes.  It is not yet known if pediatric patients…
  • Abstract Number: 412 • 2016 ACR/ARHP Annual Meeting

    Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder

    Daniel B. Horton1, Fenglong Xie2, Lang Chen2, Melissa Mannion3, Brian L. Strom4,5, Jeffrey Curtis6 and Timothy Beukelman7, 1Pediatrics, Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 4Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 5Rutgers Biomedical and Health Sciences, New Brunswick, NJ, 6Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose:  Diabetes mellitus (DM) and hypertension (HTN) are well-known toxicities of glucocorticoids (GCs), but the risks of these complications are unclear in children with JIA.…
  • Abstract Number: 331 • 2015 ACR/ARHP Annual Meeting

    Are Metabolic Factors Associated with Shoulder Osteoarthritis? a Multicentric Study.

    Pierre-Antoine Juge1, Laure Bérard2, Salma Kotti3, Tabassome Simon4, Francis Berenbaum5, Geoffroy Nourissat6 and Jérémie Sellam7, 1Rheumatology Department, Saint-Antoine Hospital, Paris, France, 2Rheumatology Department, Le Havre Hospital, Le Havre, France, 3Unité de Recherche Clinique de l’Est Parisien, Saint-Antoine Hospital, Paris, France, 4Unité de Recherche Clinique de l'Est Parisien URCEST, Saint-Antoine Hospital, AP-HP, Univ Paris 06, Paris, France, 5Rheumatology, Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, 6Orthopedic surgery, Clinique des Maussins & St-Antoine Hospital AP-HP, Paris, France, 7Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France

    Background/Purpose: Aging, trauma and obesity are the 3 main risk factors for knee, hip and hand osteoarthritis (OA). It is noteworthy that risk factors for…
  • Abstract Number: 2243 • 2015 ACR/ARHP Annual Meeting

    Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey

    Robert Morlock1, Natalia M. Flores2, Kathy Annunziata3, Jonathan Chapnick4 and Javier Nuevo5, 14939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, 2Kantar Health, Foster City, CA, 3Kantar Health, Princeton, NJ, 4Kantar Health, Horsham, PA, 5AstraZeneca, Madrid, Spain, Madrid, Spain

    Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is caused by chronic high serum uric acid (sUA) levels (ie, hyperuricemia),…
  • Abstract Number: 2260 • 2015 ACR/ARHP Annual Meeting

    High Prevalence of Hypomagnesemia and Its Relation to BMI, Type 2 Diabetes, and Clinical Disease Measures in a VA Outpatient Rheumatology Clinic Population

    Nitika Ghattaura1, Caleb Murphy2 and Peter Valen2,3, 1Rheumatology, University of Minnesota Medical School, Minneapolis, MN, 2University of Minnesota Medical School, Minneapolis, MN, 3Rheumatology, Minneapolis VAMC, Minneapolis, MN

    Background/Purpose: Magnesium plays an essential role in multiple cellular reactions, and there is increasing interest in its role in inflammation and pain. It has been…
  • Abstract Number: 2737 • 2015 ACR/ARHP Annual Meeting

    Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program

    Jeffrey R. Curtis1, Ara Dikranian2, Alan Mendelsohn3, Koshika Soma4, Haiyun Fan3 and Chudy Nduaka3, 1University of Alabama at Birmingham, Birmingham, AL, 2San Diego Arthritis Medical Clinic, San Diego, CA, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often have comorbidities that may affect treatment response.…
  • Abstract Number: 3116 • 2015 ACR/ARHP Annual Meeting

    High Level of Inflammation Predicts the Development of Diabetes Mellitus in Patients with Psoriatic Arthritis

    Lihi Eder1, Vinod Chandran1, Richard J. Cook2 and Dafna D. Gladman1, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: To estimate trends in the prevalence of diabetes mellitus (DM) in patients with psoriatic arthritis (PsA) in comparison to the general population in Ontario,…
  • Abstract Number: 1265 • 2014 ACR/ARHP Annual Meeting

    Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase

    Pari Basharat1, Arash Lahouti H.1, Andrew L. Mammen2, Iago Pinal-Fernandez1, Tanmayee Bichile3, Thomas E. Lloyd4, Sonye K. Danoff5, Livia Casciola-Rosen6 and Lisa Christopher-Stine7, 1Medicine, Johns Hopkins University, Baltimore, MD, 2Neurology and Medicine, Johns Hopkins University, Baltimore, MD, 3Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Neurology, Johns Hopkins, Baltimore, MD, 5Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, 6Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, 7Medicine and Neurology, Johns Hopkins University, Baltimore, MD

    Background/Purpose The idiopathic inflammatory myopathies (IIM) comprise a group of autoimmune disorders that target skeletal muscle. Some IIM cases may be associated with an autoantibody…
  • Abstract Number: 1113 • 2014 ACR/ARHP Annual Meeting

    Mayor Trocanter Painful Syndrome. Treatment with Hyaluronic Acid Versus Triamcinolone Acetonide Injections. a Comparative Study

    Asuncion Acosta Sr.1, Arturo Rodriguez de la Serna2, Berta Magallares2 and Gary Sterba Sr.3, 1Hospital Santa Creu i Sant Pau, Barcelona, Spain, 2Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 3rheumatology, rheumatologist, miami, FL

    Background/Purpose: Painful syndrome of the mayor trochanter(MTPS).The treatment includes intra-bursal injections with corticosteroids.Steroids.Estimate the efficacy of the treatment with hyaluronic acid injections in comparison to…
  • Abstract Number: 1064 • 2014 ACR/ARHP Annual Meeting

    Unique Profile of Cardiovascular Risk Factors in Rheumatoid Arthritis High-Risk Populations with Insufficient Risk Control

    Ulf Müller-Ladner1, Stefan Kleinert2, Klaus Krüger3, Bianca Wittig4 and Rolf Hecker4, 1Rheumatologie und klinische Immunologie, Kerckhoff-Klinik GmbH, Abt. Rheumatologie und klinische Immunologie, Bad Nauheim, Germany, 2Rheumatologie, Praxisgemeinschaft Rheumatologie-Nephrologie, Rheumatologische Schwerpunktpraxis, Erlangen, Germany, 3Praxiszentrum St. Bonifatius, München, Germany, 4Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany

    Background/Purpose More than 50% of premature deaths in patients with rheumatoid arthritis (RA) are due to cardiovascular disease (CVD). Both the cumulative burden of inflammation…
  • Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting

    Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus

    Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom

    Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
  • Abstract Number: 514 • 2014 ACR/ARHP Annual Meeting

    Methotrexate Reduces the Frequency of Prediabetes in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

    Katja Perdan-Pirkmajer1, Sergej Pirkmajer2, Alojzija Hocevar1, ŽIga Rotar1, Natasa Gaspersic1, Sonja Praprotnik1, Matija Tomsic3 and Ales Ambrozic1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Institute of Pathophysiology, Faculty of Medicine Ljubljana, Ljubljana, Slovenia, 3Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia

    Background/Purpose Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with an increased risk of diabetes mellitus (DM). Disease-modifying anti-rheumatic drugs, including methotrexate (MTX), may…
  • Abstract Number: 178 • 2014 ACR/ARHP Annual Meeting

    The Effect of Initiating Pharmacologic Insulin on Serum Uric Acid Levels in Patients with Diabetes

    Lindsey MacFarlane1, Chih-Chin Liu2 and Daniel H. Solomon3, 1Medicine, Brigham and Women's Hospital, Boston, MA, 2Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose Substantial evidence links gout and hyperuricemia to diabetes. Previous studies report an association between increasing uric acid (UA) levels, insulin resistance, and type 2…
  • Abstract Number: 169 • 2014 ACR/ARHP Annual Meeting

    Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?

    Jasvinder A. Singh1, Rekha Ramachandaran2, Jie Zhang3, Fenglong Xie4, Shuo Yang5, Huifeng Yun6 and Jeffrey R. Curtis2, 1Department of Medicine, University of Alabama, Tuscaloosa, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, 4Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 5Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL

    Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid…
  • Abstract Number: 154 • 2014 ACR/ARHP Annual Meeting

    Cimt in Individuals with Rheumatoid Arthritis Compared to Individuals with Type2 Diabetes

    Helen Pahau Sr.1,2, Leanne Short3, Brian Haluskas4, Vibeke Videm5 and Ranjeny Thomas6, 1Diamantina Institute, The University of Queensland, Woolloongabba, Australia, 2Diamantina Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 3Cardiovascular Imaging Research Centre, University of Queensland, Woolloongabba, Australia, 4Cardiovascular Imaging Research Centre, the University of Queensland, Woolloongabba, Australia, 5Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, Trondheim University Hospital,, Trondheim, Norway, 6University of Queensland Diamantina Institute, Brisbane, Australia

    Background/Purpose It is well known that patients with RA or Type 2 diabetes (T2DM) have increased risk of atherosclerosis and CVD. Carotid ultrasound measurement of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology